Literature DB >> 26730169

Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.

Wei-Chen Lin1, Jau-Min Wong1, Chien-Chih Tung1, Ching-Pin Lin1, Jen-Wei Chou1, Horng-Yuan Wang1, Ming-Jium Shieh1, Chin-Hao Chang1, Heng-Hsiu Liu1, Shu-Chen Wei1.   

Abstract

AIM: To evaluate the correlation between fecal calprotectin (fC), C-reactive protein (CRP), and endoscopic disease score in Asian inflammatory bowel disease (IBD) patients.
METHODS: Stool samples were collected and assessed for calprotectin levels by Quantum Blue Calprotectin High Range Rapid test. Crohn's disease endoscopic index of severity (CDEIS) and ulcerative colitis endoscopic index of severity (UCEIS) were used for endoscopic lesion scoring.
RESULTS: A total of 88 IBD patients [36 patients with Crohn's disease (CD) and 52 with ulcerative colitis (UC)] were enrolled. For CD patients, fC correlated with CDEIS (r = 0.465, P = 0.005) and CRP (r = 0.528, P = 0.001). fC levels in UC patients correlated with UCEIS (r = 0.696, P < 0.0001) and CRP (r = 0.529, P = 0.0005). Calprotectin could predict endoscopic remission (CDEIS < 6) with 50% sensitivity and 100% specificity (AUC: 0.74) in CD patients when using 918 μg/g as the cut-off. When using 191 μg/g as the cut-off in UC patients, calprotectin could be used for predicting endoscopic remission (UCEIS < 3) with 88% sensitivity and 75% specificity (AUC: 0.87).
CONCLUSION: fC correlated with both CDEIS and UCEIS. fC could be used as a predictor of endoscopic remission for Asian IBD patients.

Entities:  

Keywords:  Crohn’s disease; Endoscopic score; Fecal calprotectin; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 26730169      PMCID: PMC4690187          DOI: 10.3748/wjg.v21.i48.13566

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

Review 2.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

3.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

4.  Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Ken Takeuchi; Takayuki Iida; Nobuhito Kashiwagi; Abby R Saniabadi; Isao Matsushita; Yoshihiko Sato; Naoki Kasuga; Toshihiro Nakamura
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

5.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

6.  Fecal calprotectin as a promising marker of inflammatory diseases.

Authors:  Z Paduchova; Z Durackova
Journal:  Bratisl Lek Listy       Date:  2009       Impact factor: 1.278

7.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study.

Authors:  Takayuki Yamamoto; Manabu Shiraki; Takuya Bamba; Satoru Umegae; Koichi Matsumoto
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

10.  Fecal calprotectin levels are higher in rural than in urban Chinese infants and negatively associated with growth.

Authors:  Jin-Rong Liu; Xiao-Yang Sheng; Yan-Qi Hu; Xiao-Gang Yu; Jamie E Westcott; Leland V Miller; Nancy F Krebs; K Michael Hambidge
Journal:  BMC Pediatr       Date:  2012-08-23       Impact factor: 2.125

View more
  18 in total

1.  Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis.

Authors:  Hsu-Heng Yen; Mei-Wen Chen; Yu-Yao Chang; Hsuan-Yuan Huang; Tsui-Chun Hsu; Yang-Yuan Chen
Journal:  PeerJ       Date:  2020-07-14       Impact factor: 2.984

2.  Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?

Authors:  Shu Chen Wei
Journal:  Intest Res       Date:  2016-10-17

3.  Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.

Authors:  Sun-Ho Lee; Min-Ju Kim; Kiju Chang; Eun Mi Song; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Kyung-Jo Kim; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Byong Duk Ye
Journal:  BMC Gastroenterol       Date:  2017-10-23       Impact factor: 3.067

4.  Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Authors:  Gang Peng; Huanyu Guan; Xiaoming Wang; Yue Shi
Journal:  Acta Pharm Sin B       Date:  2016-12-30       Impact factor: 11.413

Review 5.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

6.  Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

Authors:  Elham A Hassan; Haidi K Ramadan; Ali A Ismael; Khaled F Mohamed; Madiha M El-Attar; Ihab Alhelali
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

Review 7.  Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.

Authors:  Shu-Chen Wei; Ting-An Chang; Te-Hsin Chao; Jinn-Shiun Chen; Jen-Wei Chou; Yenn-Hwei Chou; Chiao-Hsiung Chuang; Wen-Hung Hsu; Tien-Yu Huang; Tzu-Chi Hsu; Chun-Chi Lin; Hung-Hsin Lin; Jen-Kou Lin; Wei-Chen Lin; Yen-Hsuan Ni; Ming-Jium Shieh; I-Lun Shih; Chia-Tung Shun; Yuk-Ming Tsang; Cheng-Yi Wang; Horng-Yuan Wang; Meng-Tzu Weng; Deng-Chyang Wu; Wen-Chieh Wu; Hsu-Heng Yen; Jau-Min Wong
Journal:  Intest Res       Date:  2017-06-12

Review 8.  Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.

Authors:  Shu-Chen Wei; Ting-An Chang; Te-Hsin Chao; Jinn-Shiun Chen; Jen-Wei Chou; Yenn-Hwei Chou; Chiao-Hsiung Chuang; Wen-Hung Hsu; Tien-Yu Huang; Tzu-Chi Hsu; Chun-Chi Lin; Hung-Hsin Lin; Jen-Kou Lin; Wei-Chen Lin; Yen-Hsuan Ni; Ming-Jium Shieh; I-Lun Shih; Chia-Tung Shun; Yuk-Ming Tsang; Cheng-Yi Wang; Horng-Yuan Wang; Meng-Tzu Weng; Deng-Chyang Wu; Wen-Chieh Wu; Hsu-Heng Yen; Jau-Min Wong
Journal:  Intest Res       Date:  2017-06-12

9.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.

Authors:  Shu-Chen Wei; Chien-Chih Tung; Meng-Tzu Weng; Jau-Min Wong
Journal:  Intest Res       Date:  2018-10-10

10.  Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study.

Authors:  Shiro Nakamura; Hirotsugu Imaeda; Hiroki Nishikawa; Masaki Iimuro; Minoru Matsuura; Hideo Oka; Junsuke Oku; Takako Miyazaki; Hirohito Honda; Kenji Watanabe; Hiroshi Nakase; Akira Andoh
Journal:  Intest Res       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.